Drug-labels.com

Novo-Etidronatecal: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Current status: Cancelled Post Market
Strength:
400 mg / 500 mg

Patient Medication Information: uses, side effects, how to take - Novo-Etidronatecal

ABOUT THIS MEDICATION

What the medication is used for:

  • Treatment and prevention of osteoporosis in postmenopausal women
  • Prevention of corticosteroid induced osteoporosis

What it does:

To understand how the NOVO-ETIDRONATECAL therapy works, it is important to understand how your body lost bone mass.

Bone is living tissue that your body constantly renews. In this normal process, your body breaks down old bone tissue and replaces it with new bone. After menopause, your body goes through many changes. One change is that your body may remove more bone than it forms. The resulting bone loss can become a condition called osteoporosis, which is a bone thinning disease that causes your bones to become weak and more likely to break. As the bones weaken, people with osteoporosis can experience broken bones, pain, loss of height and humped back.

At first, osteoporosis works ‘silently’, with no symptoms you can feel. Over time, however, it produces a harmful level of bone loss - as much as 30-40%. When this occurs, your bones become weak. They can break (fracture) during normal activities or from minor falls. Broken bones in the back (spinal fractures) from osteoporosis are very common. Spinal fractures often cause back pain,

loss of height, and a humped back. Your body cannot restore spinal fractures to normal.

Osteoporosis can also lead to fractures of the hip or wrist. A hip fracture can cause you to be hospitalized. Later you may need help with daily activities.

Osteoporosis may also be caused by corticosteroid use. Corticosteroids are drugs that may be prescribed for a variety of conditions including asthma and rheumatoid arthritis.

Doctors tested the etidronate disodium and calcium cyclical therapy in long-term studies in women with osteoporosis. The therapy successfully increased bone mass in the spine. Without therapy, women past menopause may lose bone mass every year. This loss weakens bones and makes them more likely to break.

Since it is not known how long NOVO-ETIDRONATECAL should be continued, you should discuss the need to stay on this medication with your doctor regularly to determine if NOVO-ETIDRONATECAL is still right for you.

When it should not be used:

NOVO-ETIDRONATECAL is not suitable for everyone. Do not take NOVO-ETIDRONATECAL if:

  • You have had an allergic reaction (e.g. rash, difficulty breathing) to NOVO-ETIDRONATECAL and any of its ingredients (see below)
  • You have unresolved osteomalacia (a softening of the bones due to lack of vitamin D)

What the medicinal ingredients are:

Etidronate Disodium

Calcium Carbonate

What the nonmedicinal ingredients are:

Each etidronate disodium tablet contains magnesium stearate, microcrystalline cellulose, povidone and sodium starch glycolate.

Each calcium carbonate tablet contains croscarmellose sodium, FD&C blue #2 aluminum lake, hydroxypropyl methylcellulose, microcrystalline cellulose, polyethylene glycol, silicon dioxide, stearic acid, titanium dioxide, and vegetable magnesium stearate.

Neither the etidronate disodium nor the calcium carbonate tablets contain lactose.

What dosage forms it comes in:

The NOVO-ETIDRONATECAL therapy is a cyclical regimen administered in 90 day cycles. It contains:

One Card - 14 white, etidronate disodium 400 mg tablets

Four Cards - a total of 76 blue, calcium carbonate 1,250 mg tablets (containing 500 mg elemental calcium per tablet)

Patient Information Booklet

Prescription Refill Reminder

WARNINGS AND PRECAUTIONS

BEFORE you use NOVO-ETIDRONATECAL talk to your doctor or pharmacist if:

  • You have unresolved osteomalacia (a softening of the bones due to lack of vitamin D)
  • You have a history of kidney stone formation or problems with your kidneys
  • You are pregnant or nursing. NOVO-ETIDRONATECAL is not intended for administration to pregnant women or during lactation

  • You are allergic to NOVO-ETIDRONATECAL and any of its ingredients, you should not take it
  • You have sores in the mouth. This can lead to osteonecrosis of the jaw.

    Your doctor may check if you:

    • smoke
    • have or have had teeth and/or gum disease
    • have dentures that do not fit well
    • have other relevant medical conditions at the same time, such as; low red blood cell count (called anemia)
    • if your blood cannot form clots in the normal way.

Your doctor may tell you to stop taking NOVO-ETIDRONATECAL until all sores in your mouth are healed.

  • You are taking warfarin

    • You are taking tetracycline
    • You have a gastrointestinal disorder which makes you prone to diarrhea (for example, Crohn’s disease, colitis, irritable bowel syndrome, food poisoning)
    • You have one of the following risk factors: cancer; chemotherapy, radiotherapy of the head or neck, treatment with corticosteroids, or dental problems or dental infections. If so, a dental examination and any necessary dental procedures should be considered before you start treatment with NOVO-ETIDRONATECAL.

Be sure to tell your health care providers, including doctors and dentists, about all medicines you are taking, including NOVO-ETIDRONATECAL.

INTERACTIONS WITH THIS MEDICATION

If taken with some other medicines, the effects of NOVO-ETIDRONATECAL or the effects of other medicines may be changed. Please check with your doctor or pharmacist before taking other medications with NOVO-ETIDRONATECAL.

Drugs that may interact with NOVO-ETIDRONATECAL include warfarin and tetracycline.

The following foods and medicines should not be taken within 2 hours of taking the white tablet (etidronate disodium): Antacids, vitamins with mineral supplements such as iron, calcium supplements, laxative containing magnesium and foods, especially food high in calcium, such as milk or milk products.

PROPER USE OF THIS MEDICATION

Usual dose:

The NOVO-ETIDRONATECAL Package Provides 90 Days of Therapy.

  1. 1.

    Start the therapy with the first card (white tablets)

    • Begin in the top row on Monday. This will help you remember to take your tablet each day.
    • Take 1 tablet with plenty of water at bedtime each day for 14 days. Take at least 2 hours before or after eating.
    • Finish all white tablets before taking any blue tablets.

Do Not take the white tablet within 2 hours of taking the foods or medicines listed below. They will stop the white tablet from working properly.

  • Food, especially food high in calcium, such as milk or milk products
  • Antacids
  • Vitamins with mineral supplements such as iron
  • Calcium supplements
  • Laxatives containing magnesium
  • Then, start the next cards (blue tablets)
  • Begin in the top row on Monday. If the tablet is hard to swallow, crush or chew it.
  • Take 1 tablet with plenty of water at bedtime each day, with or without food. (A few people have low stomach acid. If you do, you should take the blue tablet with food. Ask your doctor or pharmacist for more information.)

  • Finish all blue tablets on each card before going to the next card.

3 Read the refill reminder at the bottom of the box.

  • Ask your doctor or pharmacist about ordering your refill.

Overdose:

If you take too many tablets on any given day, contact your doctor immediately, regional poison control centre, or go to the nearest emergency department

Missed Dose:

If you miss a day (or more) of the treatment, do not take 2 tablets the same day. Take 1 tablet on the day you remember and continue with the therapy. Be sure to finish all the tablets on the card before you begin the tablets on the next card.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

With any medication, there is some chance of side effects. The most common side effects observed with etidronate disodium and calcium cyclical therapy are nausea and diarrhea.

You may also experience headache, inflammation of the stomach, leg cramps and joint pain.

Rarely reported side effects include confusion, a burning sensation of the tongue, hair loss, and a sensation of numbness, prickling or tingling, or painful or inflamed eyes.

Very rarely patients have reported non-healing jaw wounds while receiving drugs in this class, such as NOVO-ETIDRONATECAL. Consult your doctor if you experience persistent pain in your mouth, teeth or jaw, or if your gums or mouth heal poorly.

Very rarely patients have reported unusual fractures in their thigh bone while receiving drugs in this class. Consult your doctor if you experience new or unusual pain in your hip, groin, or thigh.

IMPORTANT SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom/EffectTalk with your doctor or pharmacistStop taking drug and call your doctor or pharmacist
Only if severeIn all cases
Uncommon (less than 1 in 100)
Allergic reaction such as: hives; skin; rash; itching✓

Eye pain, redness or

inflammation; sensitivity to light, decreased vision

✓
Osteonecrosis of the jaw:•(numbness or feeling of heaviness in the jaw, poor healing of the gums especially after dental work, loose teeth, exposed bone in mouth, pain in the mouth, teeth or jaw, sores or non-healing sores in the mouth or discharge, dry mouth, swelling or gum infections, bad breath)✓
Rare (less than 1 in 1000)
Worsening of asthma✓
IMPORTANT SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM
Symptom/EffectTalk with your doctor or pharmacistStop taking drug and call your doctor or pharmacist
Only if severeIn all cases
Blood disorders with symptoms of bleeding, bruising and increased infection✓
Skin reactions (rash, sores, blisters) involving mucous membranes✓
Pain and swelling of the tongue or esophagus (tube connecting the mouth & stomach)✓
Very Rare (less than 1 in 10,000)
Worsening of stomach and intestinal ulcers✓

New or unusual pain in

hip, groin or thigh

✓

For any unexpected effects while taking NOVO-ETIDRONATECAL, contact your doctor or pharmacist. This is not a complete list of side effects.

HOW TO STORE IT

The NOVO-ETIDRONATECAL therapy should be stored between 15°C - 30°C, protected from light and moisture. Keep out of reach of children.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be obtained by contacting Teva Canada Limited, by:

Phone: 1-800-268-4127 ext. 3;

Email: druginfo@tevacanada.com; or

Fax: 1-416-335-4472

Teva Canada Limited

30 Novopharm Court

Toronto, Ontario

Canada, M1B 2K9

www.tevacanada.com

Last revised: July 27, 2017

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02324199

Revision date stated in the text: July 27, 2017

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Novo-Etidronatecal

Rx or OTC
Prescription (Rx)?
DIN 02324199
Schedule(s) PRESCRIPTION
Active ingredient(s) Etidronate disodium 400 MG, Calcium (calcium carbonate) 500 MG
Dosage form(s) Kit, Tablet
Route(s) of administration Oral
Drug class (WHO ATC)
  1. M Musculo-skeletal system drugs
    1. M05 Drugs for treatment of bone diseases
      1. M05B Drugs affecting bone structure and mineralization
        1. M05BB Bisphosphonates, combinations affecting bone structure and mineralization
          1. M05BB01 Etidronic acid and calcium, sequential
Company TEVA CANADA LIMITED
Current status Cancelled Post Market
Current status date July 9, 2019

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.